Comprehensive Metabolic Panel
The comprehensive metabolic panel or CMP is comprised of 14 blood tests. This panel of tests is used as a screening tool for physicians. It is ordered as a routine part of an annual physical examination or checkup, used as supportive diagnostic testing for a wide range of diseases and syndromes, used for disease management, therapy monitoring, and patient safety during therapy, and during any medical intervention and post-therapy as well as drug side effect monitoring. Any abnormal results in any of these tests or in combination may provide an important initial indication of a disease state; the differential diagnosis of that state might then indicate more specialized testing to be ordered. Because this panel contains the main metabolic monitoring tests, the CMP usually provides an important screening check on the status of kidney and kidney function, liver and liver function, heart and heart status, electrolyte and body fluid balance, and other body systems. It is routinely used to monitor the status of a patient with a chronic disease such as a chronic autoimmune disease, diabetes mellitus, hypertension, cancers, chronic infections, and inflammations. The CMP includes:
- Glucose is a major energy source for body cells and tissues; it could be used as a marker for physiological changes in all our body systems. It is mainly used to diagnose and manage diabetes and diabetes-related diseases. Abnormally increased and decreased levels might be diagnostically significant.
- Calcium is the most abundant mineral element in the body. About 99% of the calcium is in the bones. The remaining calcium is distributed between the various tissues and the extracellular fluids, where it performs a vital role for many life sustaining processes such as involvement in blood coagulation, neuromuscular conduction, excitability of skeletal and cardiac muscle, enzyme activation, and the preservation of cell membrane integrity and permeability. Therefore, calcium might be used as a marker for many physiological changes and disease monitoring; however, it is mainly used for diagnosis and monitoring of bone diseases. Both increased and decreased calcium levels might be diagnostically significant.
- Albumin is the most abundant protein in human plasma and is mainly produced in the liver. It plays a role in maintaining oncotic pressure of intravascular space. It also plays an important role in transporting many substances (hormones, vitamins, drugs, other substances) throughout the body. Because the concentration of albumin drops with liver damage, kidney disease, malnutrition, inflammation, or shock, this test can be used to evaluate, diagnose, and monitor liver and kidney diseases. Disease is usually associated with decreased levels.
- Total Proteins are essential for cellular functions. Plasma protein concentration is determined by nutritional state, hepatic function, renal function, hydration and various disease states. Plasma protein concentration determines the colloidal osmotic pressure. Abnormal levels might indicate liver, kidney, and other system diseases.
- Sodium is the major cation important for maintenance of water and osmotic pressure equilibrium in the extracellular compartment. Abnormal levels (decreased and increased) are associated with many diseases and disorders.
- Potassium is predominantly an intracellular cation whose plasma level is regulated by renal excretion. Maintaining normal potassium levels is important for regulation of neuromuscular excitability, cardiac contractility and rhythm, extracellular volume, and acid-base balance. Diagnostically useful in evaluation of numerous pathological and non-pathological states.
- CO2 (carbon dioxide) or bicarbonate-carbonic acid buffer is one of the most important buffer systems in maintaining normal body fluid pH. Changes in levels might indicate change in body and blood pH, which is associated with many diseases and infections.
- Chloride is the major extracellular anion and serves to regulate the balance of extracellular fluid distribution. In addition, chloride plays an important role in maintaining normal acid–base balance and normal osmolality. Increase in chloride may occur with excessive loss of bicarbonate due to diarrhea, renal tubular acidosis, respiratory alkalosis, excessive dietary intake, dehydration, kidney failure, and salicylate poisoning.
- BUN (blood urea nitrogen) is the major end product of protein nitrogen metabolism. Urea is excreted mostly by the kidneys but minimal amounts are also excreted through sweat. Abnormally high level might be toxic and have negative impact in cellular metabolism. Mainly used for kidney diseases.
- Creatinine is a metabolic end product (waste) produced endogenously from creatine and creatine phosphate as a result of the metabolic processes of muscle. Creatinine assays are conducted for diagnostic evaluation of kidney function, for therapeutic monitoring of acute and chronic renal diseases and for monitoring kidney dialysis. Serum creatinine and urea levels are elevated in patients with renal impairment, especially in patients with decreased glomerular filtration.
- ALP (alkaline phosphatase) is found in all tissues throughout the body, but is particularly concentrated in liver, bile duct, intestine, kidney, bone, and the placenta. Liver ALP is synthesized by biliary epithelium and excreted in bile. Increased serum ALP levels provide useful but nonspecific indication of liver or bone disease. ALP levels increase with obstructive hepatobiliary disease. Increased levels are also seen in hepatic and bone metastases.
- ALT (alanine aminotransferase) is synthesized predominantly by the liver. It is used in the evaluation of liver diseases (formerly SGPT).
- AST (aspartate aminotransferase) is synthesized by many tissues including the liver. It is used in the evaluation of liver diseases but is not as specific as ALT (formerly SGOT).
- Bilirubin is a product of hemoglobin metabolism. It is transported as a complex with serum albumin to the liver. In the liver bilirubin is conjugated with glucuronic acid for solubilization and subsequent transport through the bile duct and elimination via the digestive tract. Diseases or conditions which result in production of bilirubin faster than the liver can metabolize it and cause the levels of unconjugated (indirect) bilirubin to increase. Instrinsic disease of the liver and biliary tract obstruction will cause conjugated bilirubin to increase.
- As an aid in the diagnosis, of different diseases and disorders
- Disease and disorder management and treatment monitoring
- Routine health screening and prevention
Abnormal results (both increases and decreases) of one or more can be significant and might indicate the need for additional disease or disorder specialized testing.
- Chronic diseases (autoimmune diseases, diabetes)
- Inflammation
- Trauma and burns
- Infections
- Blood disorders
- Kidney diseases
- Liver diseases
- Gastrointestinal diseases
- Cardiovascular disorders
- Disease related to the heart
- Hypertension
- Bone diseases
- Muscle disorders
- Cancer
- Congenital disorders
- Genetic disorders
- Pancreatic diseases
- Storage disorders
- Surgery
- Pregnancy
- Poisoning
- Enzyme metabolic diseases
Note: for more information see individual test utility and interpretation.
Albumin
3.4–4.7 g/dL (34–47 g/L)
Alkaline Phosphatase
38-137 IU/L
Bilirubin, Total
0.0-1.2 mg/dL
Calcium
2.15-2.55 mmol/L (8.6-10.2 mg/dL)
Carbon Dioxide
22–28 meq/L
Chloride
98-110 mEq/L
Creatinine
0-3 years: 0.1-0.7 mg/dL
3-10 years: 0.1-1.2 mg/dL
Adults:
Male - 0.67-1.17 mg/dL
Female – 0.51-0.95 mg/dL
Glucose
70-99 mg/dL
Potassium
3.5-5.0 mEq/L
Protein, Total
6.0-8.0 g/dL
AST (SGOT)
0-35 U/L
ALT (SGPT)
0-35 U/L
Sodium
136-145 mEq/L
Urea Nitrogen (BUN)
8-20 mg/dL
A/G Ratio (calculated)
1.3-2.5
Globulin (calculated)
2.1-3.7 g/dL
Anion Gap (calculated)
6-22
Estimated Glomerular Filtration Rate (eGFR) (calculated)
Greater than 60 mL/min/1.73 m2
Serum (SST), or Plasma Oxalate (Grey).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
1-3 days.
- Urol Int. 2007;79 Suppl 1:20-5. [PMID: 17726348]
- Clin Nutr. 2001;20:477. [PMID: 11883995]
- J Am Diet Assoc. 2004;104:1258. [PMID: 15281044]
- Addict Behav. 2004;29:1427. [PMID: 15345274]
- Biochem. 1995 Feb;28(1):1-29. [PMID: 7720223]
- Clin Med. 2002 Sep-Oct;2(5):406-9. [PMID: 12448585]
- Clin Gastroenterol Hepatol. 2005;3:852. [PMID: 16234021]
- CMAJ. 2005;172:367. [PMID: 15684121]
- Am Fam Physician. 1992 Mar;45(3):1139-48. [PMID: 1543099]
- Am Fam Physician. 2004;69:299. [PMID: 14765767]
- Clin Lab Med. 2002;22:377. [PMID: 12134466]
- Thromb Haemost. 2002;87:74. [PMID: 11848460]
- J Thromb Haemost. 2006;4:967. [PMID: 16689743]
- Clin Lab Med. 1993 Mar;13(1):117-29 [PMID: 8462254]
- Acta Med Indones. 2007 Jul-Sep;39(3):145-50 [PMID: 17936961]
- Am Fam Physician. 2005;72:1723. [PMID: 16300034]
- Emerg Med Clin North Am. 2005;23:723. [PMID: 15982543]
- Am Fam Physician. 2003;67:1959. [PMID: 12751658]
- Diabetes Care. 2004 Jan;27 Suppl 1:S15-35. [PMID: 14693923]
- Emerg Med Clin North Am. 2005;23:749. [PMID: 15982544]
- Cleve Clin J Med. 2002;69:569. [PMID: 12109642]
- Semin Dial. 2006;19:165. [PMID: 16551296]
- Jacobs DS, DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).
- McPherson R, Pincus M (eds). Henry’s Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, PA: Saunders Elsevier. (2007), p. 147.
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757